Mar 19, 2019

Lung Cancer Update – Part 2: Our interview with Dr Chaft highlights the following topics as well as cases from her practice:

• Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion: 0m0s
• Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC: 3m2s
• Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors: 6m41s
• Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies: 7m52s
• Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation: 12m10s
• Risks and benefits with osimertinib in the adjuvant setting: 14m38s
• Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer: 17m31s
• Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation: 19m5s
• Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy: 22m58s
• Management of superior vena cava syndrome in patients with lung cancer: 25m23s
• Activity and tolerability of durvalumab as consolidation therapy: 27m50s
• Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC: 29m15s
• Recognition and management of pneumonitis associated with durvalumab/radiation therapy: 30m53s
• Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC: 35m7s
• Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors: 36m54s
• Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC: 40m11s
• Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors: 42m45s
• Management of metastatic nonsquamous NSCLC in the first-line setting: 46m0s
• Perspective on the results of the Phase III IMpower150 study: 49m47s
• Selection of first-line therapy for patients with metastatic squamous NSCLC: 53m3s
• Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC: 54m44s
• Therapeutic approach for patients with metastatic small cell lung cancer: 58m18s
• Duration of therapy with immune checkpoint inhibitors: 1h0m23s
• Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors: 1h2m18s
• Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib: 1h4m40s
• Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib: 1h7m21s

Select publications